Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. We intend to leverage our competencies and resources to positively impact human health.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q1 2026 · $95.6MThe company’s own SEC segment disclosure.
- Zejula$30.0M31%
- Vyvgart Vyvgart Hytrulo$17.6M18%
- Nuzyra$16.3M17%
- Optune$12.1M13%
- Qinlock$9.0M9%
- XACDURO$8.6M9%
- Other (2)$2.1M2%
Zai Lab Limited (ZLAB) reported revenue of $100M in Q1 2026 (quarter ended March 31, 2026), down 6.5% from the same quarter a year earlier. That came with a gross margin of 62% and net loss of $51M. For the full year FY2025, revenue was $460M (+15% year on year) and net income −$176M. Its largest product in 2026-Q1 was Zejula at $30M, 31% of the disclosed total, just ahead of Vyvgart Vyvgart Hytrulo at 18%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.